Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
Some genetic disorders—such as cystic fibrosis, hemophilia and Tay Sachs disease—involve many mutations in a person's genome, ...
EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within ...
A one-time gene therapy using a patient’s own stem cells has effectively cured a deadly immune disorder in 95% of treated ...
There are currently no available treatment options for more than 90% of the approximately 7,000 rare diseases identified to ...
The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
Pharmaceutical Technology on MSN
Affinia raises $40m for gene therapy development
Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA) ...
The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across ...
Pharmaceutical Technology on MSN
Galapagos to shutter cell and gene therapy unit
The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...
17h
AGC Biologics Partners with Rarity PBC to Advance Life-Saving Gene Therapy for "Bubble Baby Disease"
AGC Biologics, your friendly CDMO expert, announced an agreement to provide comprehensive development and manufacturing for Rarity PBC's gene therapy.
ICH gives CGT developers a regulatory framework that finally matches the speed and flexibility their groundbreaking therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback